• Specific HLA class II alleles are risk factors for cGVHD in HLA-identical female-to-male transplantat relying on full-length DBY presenting capability.

  • Full-length DBY complexed with HLA class II on vascular endothelium directly contribute to the antibody-mediated pathogenesis of cGVHD.

Chronic graft-versus-host disease (cGVHD) is a multiorgan syndrome with clinical features resembling those of autoimmune diseases. Thus, understanding commonalities in the pathophysiology of cGVHD and autoimmune diseases, such as the presence of disease-risk HLA alleles, is imperative for developing novel therapies against cGVHD. Alloantibodies against H-Y antigens encoded on the Y-chromosome are well-described risk factors for cGVHD in female-to-male transplantation. However, because H-Y antigens generally localize intracellularly in the male reproductive organs, how they emerge at affected organ levels remains elusive. Here, by analyzing nationwide registry data stratified per donor–recipient sex, we identified specific HLA class II alleles that contributed to susceptibility to male cGVHD after transplantation from HLA-identical female siblings (HLA-DRB1∗15:02: hazard ratio, 1.28; 95% confidence interval, 1.03-1.58; P = .025). Coexpression of HLA-DRB1∗15:02 efficiently transported full-length H-Y antigens, especially DBY, to the surface. The presence of alloantibodies against DBY/HLA class II complexes significantly predicted the occurrence of cGVHD (68.8% vs 31.7% at 1 year; P = .002). Notably, the ability of HLA class II molecules to transport and present DBY to alloantibodies was closely associated with the susceptibility of HLA class II alleles to cGVHD. DBY specifically colocalized with HLA class II molecules on the dermal vascular endothelium in cGVHD and provoked complement-dependent cytotoxicity. Moreover, these complexes were observed in some male leukemic cells. Altogether, these findings suggest that vascular endothelial cells facilitate alloantibody-mediated cGVHD and highlight that alloantibodies against DBY/HLA class II complexes could be common targets for cGVHD and a graft-versus-leukemia effect.

1.
MacDonald
KP
,
Hill
GR
,
Blazar
BR
.
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies
.
Blood
.
2017
. ;
129
(
1
):
13
-
21
.
2.
Rozmus
J
.
Monogenic immune diseases provide insights into the mechanisms and treatment of chronic graft-versus-host disease
.
Front Immunol
.
2020
. ;
11
:
574569
.
3.
Zeiser
R
,
Blazar
BR
.
Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?
.
Blood
.
2016
. ;
127
(
25
):
3117
-
3126
.
4.
Song
Q
,
Kong
X
,
Martin
PJ
,
Zeng
D
.
Murine models provide new insights into pathogenesis of chronic graft-versus-host disease in humans
.
Front Immunol
.
2021
. ;
12
:
700857
.
5.
Flowers
ME
,
Inamoto
Y
,
Carpenter
PA
, et al
.
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health Consensus Criteria
.
Blood
.
2011
. ;
117
(
11
):
3214
-
3219
.
6.
Kanda
J
,
Nakasone
H
,
Atsuta
Y
, et al
.
Risk factors and organ involvement of chronic GVHD in Japan
.
Bone Marrow Transplant
.
2014
. ;
49
(
2
):
228
-
235
.
7.
Miklos
DB
,
Kim
HT
,
Miller
KH
, et al
.
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
.
Blood
.
2005
. ;
105
(
7
):
2973
-
2978
.
8.
Nakasone
H
,
Tian
L
,
Sahaf
B
, et al
.
Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans
.
Blood
.
2015
. ;
125
(
20
):
3193
-
3201
.
9.
Paul
J
,
Nakasone
H
,
Sahaf
B
, et al
.
A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation
.
Haematologica
.
2019
. ;
104
(
7
):
e314
-
e317
.
10.
Zinn
AR
,
Alagappan
RK
,
Brown
LG
,
Wool
I
,
Page
DC
.
Structure and function of ribosomal protein S4 genes on the human and mouse sex chromosomes
.
Mol Cell Biol
.
1994
. ;
14
(
4
):
2485
-
2492
.
11.
Subrini
J
,
Turner
J
.
Y chromosome functions in mammalian spermatogenesis
.
Elife
.
2021
. ;
10
:
e67345
.
12.
Ditton
HJ
,
Zimmer
J
,
Kamp
C
,
Rajpert-De Meyts
E
,
Vogt
PH
.
The AZFa gene DBY (DDX3Y) is widely transcribed but the protein is limited to the male germ cells by translation control
.
Hum Mol Genet
.
2004
. ;
13
(
19
):
2333
-
2341
.
13.
Godfrey
AK
,
Naqvi
S
,
Chmátal
L
, et al
.
Quantitative analysis of Y-chromosome gene expression across 36 human tissues
.
Genome Res
.
2020
. ;
30
(
6
):
860
-
873
.
14.
Jagasia
MH
,
Greinix
HT
,
Arora
M
, et al
.
National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report
.
Biol Blood Marrow Transplant
.
2015
. ;
21
(
3
):
389
-
401.e1
.
15.
Dendrou
CA
,
Petersen
J
,
Rossjohn
J
,
Fugger
L
.
HLA variation and disease
.
Nat Rev Immunol
.
2018
. ;
18
(
5
):
325
-
339
.
16.
Jin
H
,
Arase
N
,
Hirayasu
K
, et al
.
Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility
.
Proc Natl Acad Sci U S A
.
2014
. ;
111
(
10
):
3787
-
3792
.
17.
Tanimura
K
,
Jin
H
,
Suenaga
T
, et al
.
β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome
.
Blood
.
2015
. ;
125
(
18
):
2835
-
2844
.
18.
Hiwa
R
,
Ohmura
K
,
Arase
N
, et al
.
Myeloperoxidase/HLA class II complexes recognized by autoantibodies in microscopic polyangiitis
.
Arthritis Rheumatol
.
2017
. ;
69
(
10
):
2069
-
2080
.
19.
Sugawara
E
,
Kato
M
,
Kudo
Y
, et al
.
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts
.
Autophagy
.
2020
. ;
16
(
5
):
946
-
955
.
20.
Tsuji
H
,
Ohmura
K
,
Jin
H
, et al
.
Anti-double-stranded DNA antibodies recognize DNA presented on HLA class II molecules of systemic lupus erythematosus risk alleles
.
Arthritis Rheumatol
.
2022
. ;
74
(
1
):
105
-
111
.
21.
Jin
H
,
Kishida
K
,
Arase
N
, et al
.
Abrogation of self-tolerance by misfolded self-antigens complexed with MHC class II molecules
.
Sci Adv
.
2022
. ;
8
(
9
):
eabj9867
.
22.
Atsuta
Y
.
Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)
.
Int J Hematol
.
2016
. ;
103
(
1
):
3
-
10
.
23.
Kanda
J
.
Scripts for TRUMP data analyses part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation
.
Int J Hematol
.
2016
. ;
103
(
1
):
11
-
19
.
24.
Giralt
S
,
Ballen
K
,
Rizzo
D
, et al
.
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research
.
Biol Blood Marrow Transplant
.
2009
. ;
15
(
3
):
367
-
369
.
25.
Przepiorka
D
,
Weisdorf
D
,
Martin
P
, et al
.
1994 consensus conference on acute GVHD grading
.
Bone Marrow Transplant
.
1995
. ;
15
(
6
):
825
-
828
.
26.
Sullivan
KM
,
Agura
E
,
Anasetti
C
, et al
.
Chronic graft-versus-host disease and other late complications of bone marrow transplantation
.
Semin Hematol
.
1991
. ;
28
(
3
):
250
-
259
.
27.
Kanda
Y
.
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
.
Bone Marrow Transplant
.
2013
. ;
48
(
3
):
452
-
458
.
28.
Zorn
E
,
Miklos
DB
,
Floyd
BH
, et al
.
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation
.
J Exp Med
.
2004
. ;
199
(
8
):
1133
-
1142
.
29.
Porcheray
F
,
Miklos
DB
,
Floyd
BH
, et al
.
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation
.
Transplantation
.
2011
. ;
92
(
3
):
359
-
365
.
30.
Söderberg
O
,
Gullberg
M
,
Jarvius
M
, et al
.
Direct observation of individual endogenous protein complexes in situ by proximity ligation
.
Nat Methods
.
2006
. ;
3
(
12
):
995
-
1000
.
31.
Cresswell
P
.
Invariant chain structure and MHC class II function
.
Cell
.
1996
. ;
84
(
4
):
505
-
507
.
32.
Laurin
D
,
Spierings
E
,
van der Veken
LT
, et al
.
Minor histocompatibility antigen DDX3Y induces HLA-DQ5-restricted T cell responses with limited TCR-Vbeta usage both in vivo and in vitro
.
Biol Blood Marrow Transplant
.
2006
. ;
12
(
11
):
1114
-
1124
.
33.
Krummey
SM
,
Gareau
AJ
.
Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection
.
Front Immunol
.
2022
. ;
13
:
916200
.
34.
Reynisson
B
,
Barra
C
,
Kaabinejadian
S
,
Hildebrand
WH
,
Peters
B
,
Nielsen
M
.
Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data
.
J Proteome Res
.
2020
. ;
19
(
6
):
2304
-
2315
.
35.
Popli
R
,
Sahaf
B
,
Nakasone
H
,
Lee
JY
,
Miklos
DB
.
Clinical impact of H-Y alloimmunity
.
Immunol Res
.
2014
. ;
58
(
2-3
):
249
-
258
.
36.
Pidala
J
,
Lee
SJ
,
Ahn
KW
, et al
.
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation
.
Blood
.
2014
. ;
124
(
16
):
2596
-
2606
.
37.
Morishima
Y
,
Kashiwase
K
,
Matsuo
K
, et al
.
Biological significance of HLA locus matching in unrelated donor bone marrow transplantation
.
Blood
.
2015
. ;
125
(
7
):
1189
-
1197
.
38.
Fuchs
EJ
,
McCurdy
SR
,
Solomon
SR
, et al
.
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
.
Blood
.
2022
. ;
139
(
10
):
1452
-
1468
.
39.
Stern
M
,
Passweg
J
,
Tiercy
JM
, et al
.
Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation
.
Biol Blood Marrow Transplant
.
2006
. ;
12
(
11
):
1169
-
1175
.
40.
Battiwalla
M
,
Hahn
T
,
Radovic
M
, et al
.
Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence
.
Blood
.
2006
. ;
107
(
5
):
1970
-
1973
.
41.
Battiwalla
M
,
Ellis
K
,
Li
P
, et al
.
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies
.
Biol Blood Marrow Transplant
.
2012
. ;
18
(
8
):
1302
-
1308
.
42.
Matsuda
Y
,
Hara
J
,
Osugi
Y
, et al
.
Serum levels of soluble adhesion molecules in stem cell transplantation-related complications
.
Bone Marrow Transplant
.
2001
. ;
27
(
9
):
977
-
982
.
43.
Biedermann
BC
,
Tsakiris
DA
,
Gregor
M
,
Pober
JS
,
Gratwohl
A
.
Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease
.
Bone Marrow Transplant
.
2003
. ;
32
(
11
):
1077
-
1084
.
44.
Lelas
A
,
Greinix
HT
,
Wolff
D
,
Eissner
G
,
Pavletic
SZ
,
Pulanic
D
.
Von Willebrand factor, factor VIII, and other acute phase reactants as biomarkers of inflammation and endothelial dysfunction in chronic graft-versus-host disease
.
Front Immunol
.
2021
. ;
12
:
676756
.
45.
Martires
KJ
,
Baird
K
,
Steinberg
SM
, et al
.
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease
.
Blood
.
2011
. ;
118
(
15
):
4250
-
4257
.
46.
Grkovic
L
,
Baird
K
,
Steinberg
SM
, et al
.
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity
.
Leukemia
.
2012
. ;
26
(
4
):
633
-
643
.
47.
Biedermann
BC
,
Sahner
S
,
Gregor
M
, et al
.
Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease
.
Lancet
.
2002
. ;
359
(
9323
):
2078
-
2083
.
48.
Christopher
MJ
,
Petti
AA
,
Rettig
MP
, et al
.
Immune escape of relapsed AML cells after allogeneic transplantation
.
N Engl J Med
.
2018
. ;
379
(
24
):
2330
-
2341
.
49.
Toffalori
C
,
Zito
L
,
Gambacorta
V
, et al
.
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
.
Nat Med
.
2019
. ;
25
(
4
):
603
-
611
.
50.
Tamaki
M
,
Kameda
K
,
Kimura
SI
, et al
.
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors
.
Blood Adv
.
2022
. ;
6
(
6
):
1895
-
1903
.
You do not currently have access to this content.
Sign in via your Institution